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tensive patients is a cost effective method of preventing stroke
and myocardial infarction (MI) among patients not taking
diuretics. METHODS: A decision analytic model was developed
to compare the costs of antihypertensive therapy, stroke, and MI
for patients screened for the a-adducin gene variant versus those
not screened (standard care). The outcomes possible for each
group were: no event, stroke, or MI. Epidemiological data for
the risk of stroke, MI and the effect of the a-adducin gene variant
were obtained from the literature. We assumed patients in the
standard care group continued on their current anti-hypertensive
regimen. In the screened patient group, we assumed 90% with
the a-adducin gene variant switched to a diuretic, whereas those
with the wild-type a-adducin gene continued their current
regimen. Cost data were obtained from the literature, and the
cost of the screening test was estimated based on currently avail-
able commercial tests for other gene variants. The analysis was
conducted in 2003 dollars from the payer perspective. One-way
sensitivity analyses were performed to test the robustness of the
results. RESULTS: The screening strategy saved $1427 and
increased Quality of Adjusted Life Years (QALY) by 0.10. When
the screening test was assumed to cost $2000, the incremental
cost increased to $6600/QALY. When only 10% of patients were
assumed to have switched to diuretics based on their screen 
result the incremental cost effectiveness ratio increased to
$56,317/QALY. CONCLUSIONS: The results of this cost effec-
tiveness analysis suggest that under most circumstances, screen-
ing patients on antihypertensive therapy for the a-adducin gene
variant is a cost saving or cost effective strategy.
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CLAIM-BASED DRUG WASTAGE ESTIMATION: HOW HIDDEN
REFILL BEHAVIOR CAN HELP
Xiao Q, Marks AS
Caremark Inc, Northbrook, IL, USA
OBJECTIVES: Dispensing large quantities of maintenance drugs
often causes concern of wastage due to patients changing med-
ication types. This study examines the prescription claims related
to patients changing medications, and establishes a new method
to estimate drug wastage and explores its implications on drug
dispensing policies. METHODS: The prescription claims of new
patients of three drug classes (satins, SSRIs and PPIs) in 2002
were extracted from Caremark’s prescription claim database.
Drug changes were identiﬁed and wasted days of supply were
calculated using the overlapped days between the new script ﬁll
date and the old script due date. The distributions of the wasted
days of the three drug classes in 90-day-supply reﬁlls at mail and
30-day-supply reﬁlls at retail were analyzed. Based on the ﬁnd-
ings, a separation process was developed to estimate average
wastage using clustering methods. RESULTS: The distributions
of the wasted days appeared to be bimodal. One component 
of the bimodal distributions was consistent with overlapping
pattern of non-changing drug reﬁlling patterns. The wastage
population identiﬁed two separate behavioral groups: reﬁll-
change people who change medications when their current med-
ications are due to reﬁll, and early-change people who change
medications even though they still have signiﬁcant amount of
existing medications. Reﬁll-change people were not likely to
waste medications. The new wastage rates were 0.4% in 90-
day supply and 0.2% in 30-day supply for statins, 0.2% in 90-
day supply and 0.5% 30-day supply for SSRIs and 1.2% in 
90-day supply and 0.9% in 30-day supply for PPIs. CONCLU-
SIONS: This study discovered a bimodal pattern in wastage. A
portion of the wastage implies hidden reﬁll pattern. Based on
these ﬁndings, this study establishes a new way to estimate pre-
scription drug wastage using claim data and shows that dis-
pensing large quantities does not necessarily lead to higher
wastage of medications.
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Viswanathan H, Bharmal M,Thomas III J
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OBJECTIVES: The study objectives were to determine the preva-
lence and correlates of potentially inappropriate prescribing
among the ambulatory elderly using 2003 Beers criteria.
METHODS: Retrospective analysis was conducted of the 2001
public use ﬁles of the National Ambulatory Medical Care Survey
and the National Hospital Ambulatory Medical Care Survey. A
total of 7243 visits by individuals over 64 years old with at least
one prescription were analyzed. The 2003 Beers criteria were
used to deﬁne potentially inappropriate medications irrespective
of disease, dose, and duration. Multivariate logistic regression
using generalized estimating equations was performed to
examine associations between age, gender, race, payment source,
reason for visit, referral status, sharing of care by other phy-
sicians, number of medications, ambulatory setting type, 
metropolitan location of practice, and geographic region with
potentially inappropriate prescribing. Data was analyzed using
SAS 8.2 and SUDAAN 8.02. An alpha of 0.05 was required for
signiﬁcance. RESULTS: Potentially inappropriate medications
were prescribed in 17.8 million ofﬁce-based ambulatory visits
and 930,211 hospital-based ambulatory visits, 11.9% of all
ambulatory visits made by the elderly. The most common drug
classes were narcotic analgesics, antihistamines, and antiar-
rhythmic agents. Among all variables examined, location of
practice, referral status, and number of medications were asso-
ciated with receipt of a potentially inappropriate medication.
After adjusting for other risk factors, visits made in metropoli-
tan areas or by referred patients were more than twice as likely
to involve a potentially inappropriate medication. In addition,
compared with patients taking one medication, those taking two
(Odds Ratio (OR) = 2.64, 95% CI = 1.41–4.95), three (OR =
6.85, 95% CI = 3.15–14.88), or four or more medications (OR
= 7.43, 95% CI = 4.36–12.67) were more likely to receive a
potentially inappropriate medication. CONCLUSIONS: Poten-
tially inappropriate prescriptions were prevalent in nearly 12%
of ambulatory visits made by the elderly in 2001. More prospec-
tive efforts to improve prescribing practices and prevent drug-
related problems among the elderly are needed.
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OBJECTIVES: Retrospective Drug Utilization Review (RDUR)
can be effective in reducing drug-related problems and adverse
health outcomes. This study examined whether RDUR interven-
tion letters to prescribers impacted the recurrence of drug-
prescribing programs (exceptions) and evaluated the subsequent
effect on utilization of health care services. METHODS: Data
used were from combined pharmacy and medical claims from
January 2002 through November 2003. To assess the impact of
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intervention letters on the recurrence of exceptions, multiple
regression models were developed using prescriber-level mean
time (in days) between exceptions. In addition, the effect on
medical costs and utilization was measured for a subset of data
using a pre-post design with a control group. Pre-post periods
were deﬁned as 120 days before and after the date of interven-
tion letters dated between May 1 and August 31, 2003. Controls
were selected by matching to intervention cases using the propen-
sity score methods. Sensitivity analysis was performed using
varying time windows and bootstrap samples. Outcomes related
to PMPM inpatient admissions, emergency room visits, and
physician ofﬁce visits were analyzed. RESULTS: Of 51,214 pre-
scribers who had two or more exceptions during the 23-month
time period, 6233 (12%) were randomly selected to receive inter-
vention letters (ranging from one to 19). Model coefﬁcients indi-
cated that the time to exception was longer by 6.5 days (p <
0.001) as prescribers received additional intervention letters,
after adjusting for the number of exceptions, severity level, and
average patient age. There were no signiﬁcant differences in med-
ication costs from pre to post time periods, or between groups
(study vs. control). However, the study group had fewer PMPM
inpatient admissions and emergency room visits. CONCLU-
SIONS: Retrospective drug utilization review processes can have
a positive effect in delaying next exceptions for prescribers and
reducing utilization of health care services.
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OBJECTIVE: Budget impact analysis (BIA) evaluates ﬁnancial
impacts of new technologies; it provides valuable information to
decision-makers with a budget concern. This study proposes a
dynamic model to incorporate variations in patients mix and
drug prices over time in BIA. METHODS: The dynamic model
is an inhomogeneous Markov Chain model. It contains three
Markov states categorized by whether a patient’s illness was
treated with a generic drug, an existing brand-name drug, or the
new brand-name drug. At each cycle, the model modiﬁes the
patient cohort by accounting for newly diagnosed incident cases
and exiting cases due to cure or death. Also considered is a pos-
sible difference in the preference of treatment selection between
the current and newly diagnosed patients. We conducted BIA on
a simulated data using the Bayesian approach and presented the
results in a probabilistic plot similar to the cost-effectiveness
acceptability curve. A case study comparing the budget impact
of including versus excluding a new drug in a health plan was
used to demonstrate our method. The case study assumes the
perspective of a payer and a time frame of ﬁve years. RESULTS:
Results based on the simulated data showed that adding the 
new drug to the plan is associated with a budget increase in the
short run but would reduce the budget in the long run. The prob-
ability that including the new drug would increase in the budget
by 10% is 9%, 26% in a one- and two-year study timeframe,
and it becomes cost neutral in the ﬁve-year timeframe. CON-
CLUSIONS: The proposed model provides a powerful frame-
work to examine the time-varying parameters in BIA and
generates estimates that better reﬂect health care market in the
real world.
ADHERENCE/COMPLIANCE
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CAPTURING PATIENT-REPORTED COMPLIANCE DATA IN 
A NINE-COUNTRY PRODUCT REGISTRY USING MEMS 
CAP DEVICES
Steffan P, Becker R, Sama P
Ovation Research Group, Highland Park, IL, USA
OBJECTIVE: To capture patient compliance data on a pre-
scribed concomitant medication of an international product 
registry. The data needed to be collected in an accurate, timely,
non-burdensome, and cost-effective manner. METHODS:
Several patient compliance measurement options were consid-
ered but not selected including: physician ofﬁce surveys, tele-
phone surveys, and proxy responses. We chose the Medication
Electronic Monitoring Systems (MEMS), which is a standard
plastic vial, and a cap for the vial that contains a micro-
electronic circuit that records times when the cap is opened 
and closed. MEMS bottles and caps were given to participating
clinicians with speciﬁc instructions for distribution to registry
participants. MEMS were to be ﬁlled with a full 6-month pre-
scription of the concomitant medication and distributed to
patients at discharge. Patients were to be instructed to complete
the prescribed regimen and received instructions on the use and
purpose of the MEMS. They also were to receive written instruc-
tions on returning the MEMS to their clinician after 6 months.
The clinicians were to return the MEMS caps to a centralized
data processing center in the United States for analysis.
RESULTS: MEMS were distributed to 707 patients, by 43 physi-
cians, in 9 countries on 6 continents. The cost of distribution
(including devices and mailings) was approximately $100.00 per
patient. Delays in receiving MEMS caps from patients in a timely
manner were experienced, as were delays in receiving MEMS
caps from sites. Of the 240 MEMS devices administered, 26%
returned the cap for analysis and 24% of the MEMS caps yielded
analyzable data. CONCLUSION: Compared to other methods
of collecting compliance data on a large international scale,
MEMS provided a non-burdensome manner for collecting data.
However, the low return rate indicates that this process must be
monitored closely to maximize results, minimize costs and to
ensure that patient utilization does not vary.
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OBJECTIVE: This study compares two compliance measure-
ments, a telephone patient-reported survey and the Medication
Electronic Monitoring System (MEMS), for a 12-month inter-
national registry studying re-intervention rates for interventional
cardiology. METHODS: Patients were prescribed a 6-month
anti-platelet drug regimen upon discharge from the hospital.
Drug was supplied to all patients in a MEMS bottle, which con-
tained an electronic cap that recorded internally the date and
time the bottle was opened. At the end of six months, patients
were to return the empty bottle to their provider for analysis.
Patients included in this study were also contacted via telephone
quarterly to recall their medication compliance status. The agree-
ment between the two methods was evaluated using the weighted
Cohen’s kappa statistic (Kw). RESULTS: Of the 778 patients
enrolled in the registry, 707 were given MEMS devices, and of
those patients, 642 have reached the 6-month endpoint. A total
